US President Donald Trump’s plan to drop a 200 per cent tariff bomb on Australian pharmaceuticals is set to “screw over” the ...

Hemlibra safely reduces bleeding episodes in people with hemophilia A without inhibitors, per a review study that confirmed ...

Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Researchers have created liver tissue that grows its own blood vessels, improving research into hemophilia and liver damage.

A new study found that patients with hemophilia A could safely switch directly from emicizumab to Mim8 without a washout period, meaning they did not need to stop treatment before starting the new ...

Certain immune markers in the blood may help predict ITI response among hemophilia A patients given immune tolerance ...

Elton John and Jeanine White, the mother of Ryan White, urge Congress not to cut funding for lifesaving HIV and AIDS programs ...

Four months later, in his name, Congress nearly unanimously enacted the Ryan White CARE Act – providing essential HIV care ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...